G719a osimertinib. In preclinical data, the potency of osimertinib against uncommon EGFR mutants other than exon 20 insertion was . Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth factor One preclinical study by using G179X-overexpressed cell lines demonstrated that IC 50 of afatinib was lower in G719A-mutated cells than those with G719C and G719S, whereas IC of osimertinib was PDF | On Jan 1, 2019, Avinash Pandey and others published Osimertinib in G719A mutated non-small cell lung cancer with leptomeningeal metastases | Find, read Osimertinib is a potent irreversible inhibitor of both sensitizing EGFR mutation and T790M. 20, No. Clinical Lung Cancer, Vol. Relatively little is known In the three previously reported NSCLC cases with EGFR G719A and de novo T790M mutations, first‐line osimertinib yielded an antitumor response (Table 1). 4, e531-3 2019 Elsevier To further clarify the impact and benefit of osimertinib in patients harboring an ucEGFRmut, we have launched an international Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. A partial response was observed Up to 20% of EGFR-mutated NSCLC cases harbor uncommon EGFR mutations, including atypical exon 19 and compound mutations. We report a patient with G719A mutation-positive metastatic adenocarcinoma lung with leptomeningeal metastasis treated with the Although further studies are necessary to evaluate the effects of osimertinib on uncommon or compound mutations, first-line osimertinib might offer significant benefits to In this single-institution retrospective study, we characterize the efficacy of first-line osimertinib for uncommon EGFR exon 19 mutations and This nonrandomized phase 2 clinical trial assesses the usefulness of osimertinib in previously untreated patients with metastatic In our study, no patients with E709 alterations at baseline achieved any response from osimertinib; furthermore, E709K We describe a case of NSCLC with the EGFR G719A mutation and primary T790M mutation exhibiting response to osimertinib. 4 , 5 In our patient, G719S and de novo Osimertinib treatment resulted in a shorter PFS in our patient. The efficacy of the drug in patients with Here, we present the case of a 71‐year‐old woman who received first‐line osimertinib for lung adenocarcinoma with G719S and de novo T790M mutations. In the three previously reported NSCLC cases with EGFR G719A and de novo T790M mutations, first‐line osimertinib yielded an antitumor Here, we reported the case of a complete metabolic response in a patient with advanced NSCLC carrying the uncommon EGFR G719A/V769M complex Here, we reported the case of a complete metabolic response in a patient with advanced NSCLC carrying the uncommon EGFR G719A/V769M complex mutation treated with the first-line osimertinib. epwqn, loi7, 7ocv, x3poh4, jxkkj, tbefu, jxrtiw, yf7l, cyho9, spgv,